Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism—A systematic review
Research output: Contribution to journal › Review › Research › peer-review
Standard
Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism—A systematic review. / Buch, Kristian; Gunmalm, Victoria; Andersson, Michael; Schwarz, Peter; Brøns, Charlotte.
In: Cancer Medicine, Vol. 8, No. 1, 2019, p. 238-245.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism—A systematic review
AU - Buch, Kristian
AU - Gunmalm, Victoria
AU - Andersson, Michael
AU - Schwarz, Peter
AU - Brøns, Charlotte
PY - 2019
Y1 - 2019
N2 - Introduction: Breast cancer (BC) is the most common cancer among women worldwide. With increasing survival rates, focus has expanded to long-term adverse effects of adjuvant chemotherapy and/or aromatase inhibitors. Weight gain during chemotherapy has been well documented, but the underlying mechanisms remain unclear. A change in glucose and insulin metabolism is a possible consequence. Methods: We searched PubMed on the 4th of May 2018, and found eight articles that compared measurements of glucose and insulin before and after chemotherapy and/or aromatase inhibitors in woman with BC. Results: A general trend of increased glucose and insulin is seen and likely to be caused by weight gain and/or changes in body composition as a consequence of adjuvant treatment of BC. Discussion: Due to methodological limitations including short follow-up times and small sample sizes, further studies are required to better describe metabolic consequences of adjuvant chemotherapy and/or aromatase inhibitors. Future studies could help identify patients in high-risk of developing cardiometabolic disease after BC treatment.
AB - Introduction: Breast cancer (BC) is the most common cancer among women worldwide. With increasing survival rates, focus has expanded to long-term adverse effects of adjuvant chemotherapy and/or aromatase inhibitors. Weight gain during chemotherapy has been well documented, but the underlying mechanisms remain unclear. A change in glucose and insulin metabolism is a possible consequence. Methods: We searched PubMed on the 4th of May 2018, and found eight articles that compared measurements of glucose and insulin before and after chemotherapy and/or aromatase inhibitors in woman with BC. Results: A general trend of increased glucose and insulin is seen and likely to be caused by weight gain and/or changes in body composition as a consequence of adjuvant treatment of BC. Discussion: Due to methodological limitations including short follow-up times and small sample sizes, further studies are required to better describe metabolic consequences of adjuvant chemotherapy and/or aromatase inhibitors. Future studies could help identify patients in high-risk of developing cardiometabolic disease after BC treatment.
KW - breast cancer
KW - chemotherapy
KW - glucose
KW - insulin
KW - weight gain
U2 - 10.1002/cam4.1911
DO - 10.1002/cam4.1911
M3 - Review
C2 - 30561133
AN - SCOPUS:85060556722
VL - 8
SP - 238
EP - 245
JO - Cancer Medicine
JF - Cancer Medicine
SN - 2045-7634
IS - 1
ER -
ID: 230250328